Advances in non-surgical management of primary liver cancer

Hepatocellular carcinoma(HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide. There have been great improvements in the diagnosis and treatment of HCC in recent years, but the problems, including difficult diagnosis at early stage, quick progression...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 44; pp. 16630 - 16638
Main Authors Chen, Xiao, Liu, Hai-Peng, Li, Mei, Qiao, Liang
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 28.11.2014
Subjects
Ablation
Ablation Techniques - adverse effects
Ablation Techniques - trends
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biotherapy
carcin
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Chemoembolization, Therapeutic - adverse effects
Chemoembolization, Therapeutic - trends
Hepatocellu-lar
Humans
Immunotherapy
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Molecular Targeted Therapy
Neoplasm Staging
Patient Selection
Radiotherapy
Risk Factors
therapy
Topic Highlight
Treatment Outcome
Chemotherapy
Biotherapy
Radiofrequency ablation
Hepatocellular carcinoma
Ablation therapy
Radiotherapy
Percutaneous ethanol injection
Percutaneous microwave coagulation therapy
Transcatheter arterial chemoembolization
Hormonal therapy
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma(HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide. There have been great improvements in the diagnosis and treatment of HCC in recent years, but the problems, including difficult diagnosis at early stage, quick progression, and poor prognosis remain unsolved. Surgical resection is the mainstay of the treatment for HCC. However, 70%-80% of HCC patients are diagnosed at an advanced stage when most are ineligible for potentially curative therapies such as surgical resection and liver transplantation. In recent years, non-surgical management for unrespectable HCC, such as percutaneous ethanol injection, percutaneous microwave coagulation therapy, percutaneous radiofrequency ablation, transcatheter arterial chemoembolization, radiotherapy, chemotherapy, biotherapy, and hormonal therapy have been developed. These therapeutic options, either alone or in combination, have been shown to control tumor growth, prolong survival time, and improve quality of life to some extent. This review covers the current status and progress of non-surgical management for HCC.
Bibliography:Xiao Chen;Hai-Peng Liu;Mei Li;Liang Qiao;Department of General Surgery, Lanzhou University Second Hospital;Key Laboratory of Digestive System Tumors of Gansu Province;Storr Liver Unit, Westmead Millennium Institute, Department of Medicine and Western Clinical School, University of Sydney
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Author contributions: Chen X contributed to the conception, design, and creation of the first draft; Liu HP and Li M assisted with manuscript writing, the reference search, and table generation; Qiao L made considerable language edits and revisions to the manuscript, and approved the final version for publication.
Correspondence to: Liang Qiao, MD, PhD, Storr Liver Unit, Westmead Millennium Institute, Department of Medicine and Western Clinical School, University of Sydney, Westmead, NSW 2145, Australia. liang.qiao@sydney.edu.au
Telephone: +61-2-86273534
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v20.i44.16630